Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

429 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort.
Rouyer M, Oudard S, Joly F, Fizazi K, Tubach F, Jove J, Lacueille C, Lamarque S, Guiard E, Balestra A, Droz-Perroteau C, Fourrier-Reglat A, Moore N; FUJI Investigators. Rouyer M, et al. Among authors: oudard s. Br J Cancer. 2019 Dec;121(12):1001-1008. doi: 10.1038/s41416-019-0611-6. Epub 2019 Nov 13. Br J Cancer. 2019. PMID: 31719685 Free PMC article.
Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers.
Escudier B, Droz JP, Rolland F, Terrier-Lacombe MJ, Gravis G, Beuzeboc P, Chauvet B, Chevreau C, Eymard JC, Lesimple T, Merrouche Y, Oudard S, Priou F, Guillemare C, Gourgou S, Culine S; Genitourinary Group of the French Federation of Cancer Centers. Escudier B, et al. Among authors: oudard s. J Urol. 2002 Sep;168(3):959-61. doi: 10.1016/S0022-5347(05)64551-X. J Urol. 2002. PMID: 12187199 Clinical Trial.
Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy regimen followed by extended-field, full-dose radiotherapy: long-term results of the Groupe Ouest et Est des Leucémies et Autres Maladies de Sang H90-A/B Multicenter Randomized Trial.
Djeridane M, Oudard S, Escoffre-Barbe M, Lacotte-Thierry L, Desablens B, Briére J, Dib M, Cassasus P, Ghandour C, Lamy T, Lejeune F, Simon M, Traullé C, Vigier M, Maisonneuve H, Briére J, Colonna P, Andrieu JM. Djeridane M, et al. Among authors: oudard s. Cancer. 2002 Nov 15;95(10):2169-79. doi: 10.1002/cncr.10932. Cancer. 2002. PMID: 12412171 Free article. Clinical Trial.
Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM, Pfister C, Tubiana N, Ouldkaci M, Prevot G, Lucas V, Oudard S, Malet M, Cottu P, Ferrero JM, Mayeur D, Rixe O, Sun XS, Bernard O, Andre T, Tournigand C, Muracciole X, Guilhot J; Subcutaneous Administration Propeukin Program Cooperative Group. Tourani JM, et al. Among authors: oudard s. J Clin Oncol. 2003 Nov 1;21(21):3987-94. doi: 10.1200/JCO.2003.02.073. J Clin Oncol. 2003. PMID: 14581421 Clinical Trial.
[Prostate cancer: update].
Oudard S, Medioni J, Scotté F, Banu E. Oudard S, et al. Bull Cancer. 2005 Oct;92(10):865-73. Bull Cancer. 2005. PMID: 16266870 Free article. Review. French.
[Chemotherapy for prostate cancer].
Medioni J, Dionysopoulos D, Banu E, Scotté F, Beuzeboc P, Oudard S. Medioni J, et al. Among authors: oudard s. Presse Med. 2008 May;37(5 Pt 2):814-20. doi: 10.1016/j.lpm.2007.07.019. Epub 2007 Dec 21. Presse Med. 2008. PMID: 18160251 Review. French.
429 results